Valuation dashboard for Sutro Biopharma, Inc. (STRO) with P/E N/A, P/B -2.10, EV/EBITDA -0.89 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation.
Analysis Summary
Sutro Biopharma, Inc. reported revenue of $102.5M in the most recent fiscal year, growing at a 5-year CAGR of 19.1%.
Trailing-twelve-month margins: gross margin 97.2%, operating margin -309.9%, net margin -395.2%.
At the current price of $15.60, STRO has negative trailing earnings (P/E not meaningful) and an ROE of 185.30%. Market capitalisation stands at $151M.
Balance sheet quality for STRO: current ratio of 2.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -2.10 |
| EV / EBITDA | -0.89 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-70.23 |
| vs Current Price | -550.2% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| STRO | Sutro Biopharma, Inc. | $151M | 185.3% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $15.60 |
| Market Cap | $151M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 185.30% |
| Return on Invested Capital | -95.49% |
| Return on Assets | -92.89% |
| Gross Margin | 97.20% |
| Operating Margin | -309.87% |
| Net Margin | -395.25% |
Related companies: ADVM · ARTV · CNTB · DTIL · GUTS · IFRX · KLRS
Explore sector: Healthcare · Biotechnology
More sections of STRO: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks